Abstract
Globally, an estimated 85% of lung cancer in men and 47% of lung cancer in women is attributable to tobacco smoking. Tobacco dependence treatment remains the most cost-effective way to prevent morbidity and mortality from lung cancer. Several effective pharmacotherapies are available to treat tobacco dependence. However, the long-term effectiveness of these treatments has been limited because the majority of smokers who attempt to stop smoking eventually relapse. Approaching the treatment of tobacco use and dependence as a chronic disease and the development of innovative drug therapies offer new hope for the treatment of tobacco-dependent patients. The diagnosis of lung cancer provides a teachable moment to motivate patients to attempt tobacco abstinence on which clinicians should capitalize. We review the currently available pharmacologic approaches to the treatment of tobacco dependence.
Original language | English (US) |
---|---|
Pages (from-to) | 249-256 |
Number of pages | 8 |
Journal | Journal of Thoracic Oncology |
Volume | 2 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2007 |
Keywords
- Bupropion
- Drug therapy
- Nicotine
- Smoking cessation
- Tobacco use cessation
- Varenicline
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine